Effects of green tea on iron accumulation and oxidative stress in livers of iron-challenged thalassemic mice

Medicinal Chemistry

Volumn 6, Issue 2, 2010, Pages 57-64

  Saewong, T ^a   Ounjaijean, S ^a   Mundee, Y ^b   Pattanapanyasat, K ^c   Fucharoen, S ^d   Porter, J B ^e   Srichairatanakool, S ^a  

^a THAMMASAT UNIVERSITY   (Thailand)

^b CHIANG MAI UNIVERSITY   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

^d MAHIDOL UNIVERSITY   (Thailand)

^e ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Collagen; Green tea; Iron overload; Liver; Malondialdehyde; Thalassemia

Indexed keywords

COLLAGEN; DEFERIPRONE; GLUTATHIONE; GREEN TEA EXTRACT; IRON; MALONALDEHYDE; PLACEBO;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BETA THALASSEMIA; CELL INFILTRATION; COLORIMETRY; CONTROLLED STUDY; DIET; DRUG EFFECT; DRUG EFFICACY; HISTOCHEMISTRY; IRON INTAKE; IRON OVERLOAD; LEUKOCYTE; LIVER; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PORTAL VEIN; PRIORITY JOURNAL; STAINING;

ADMINISTRATION, ORAL; ANIMALS; BETA-THALASSEMIA; COLLAGEN; DIETARY SUPPLEMENTS; FERROUS COMPOUNDS; GLUTATHIONE; IRON; IRON OVERLOAD; LIVER; MALE; MALONDIALDEHYDE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OXIDATIVE STRESS; PLANT EXTRACTS; PYRIDONES; TEA;

EID: 77953510012     PISSN: 15734064     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340610791321479     Document Type: Article

References (51)

1. Cunningham, M. J.; Macklin, E. A.; Neufeld, E. J.; Cohen, A. R. Complications of beta-thalassemia major in North America. Blood, 2006, 104, 34-39.
2. Porter, J. B. Monitoring and treatment of iron overload: state of the art and new approaches. Semin. Hematol., 2005, 42, S14-18.
3. Pootrakul, P.; Breuer, W.; Sametband, M.; Sirankapracha, P.; Hershko, C.; Cabantchik, Z. I. Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded betathalassemia/ HbE patients treated with an oral chelator. Blood, 2004, 104, 1504-1510.
4. Barisani, D.; Berg, C. L.; Wessling-Resnick, M.; Gollan, J. L. Evidence for a low Km transporter for non-transferrin-bound iron in isolated rat hepatocytes. Am. J. Physiol., 1995, 269, G570-576.
5. Randell, E. W.; Parkes, J. G.; Olivieri, N. F.; Templeton, D. M. Uptake of non-transferrin-bound iron by both reductive and nonreductive processes is modulated by intracellular iron. J. Biol. Chem., 1994, 269, 16046-16053.
6. Garrick, L. M.; Dolan, K. G.; Romano, M. A.; Garrick, M. D. Nontransferrin- bound iron uptake in Belgrade and normal rat erythroid cells. J. Cell. Physiol., 1999, 178, 349-358.
7. Oudit, G. Y.; Sun, H.; Trivieri, M. G.; Koch, S. E.; Dawood, F.; Ackerley, C.; Yazdanpanah, M.; Wilson, G. J.; Schwartz, A.; Liu, P. P.; Backx, P. H. L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat. Med., 2003, 9, 1187-1194.
8. Oudit, G. Y.; Trivieri, M. G.; Khaper, N.; Liu, P. P.; Backx, P. H. Role of L-type Ca2+ channels in iron transport and iron-overload cardiomyopathy. J. Mol. Med. (Berlin, Germany), 2006, 84, 349- 364.
9. Liuzzi, J. P.; Aydemir, F.; Nam, H.; Knutson, M. D.; Cousins, R. J. Zip14 (Slc39a14) mediates non-transferrin-bound iron uptake into cells. Proc. Natl. Acad. Sci. U.S.A., 2006, 103, 13612-13617.
10. Livrea, M. A.; Tesoriere, L.; Pintaudi, A. M.; Calabrese, A.; Maggio, A.; Freisleben, H. J.; D'Arpa, D.; D'Anna, R.; Bongiorno, A. Oxidative stress and antioxidant status in beta-thalassemia major: iron overload and depletion of lipid-soluble antioxidants. Blood, 1996, 88, 3608-3614; 1996.
11. Arthur, M. J. Iron overload and liver fibrosis. J. Gastroenterol. Hepatol., 1996, 11, 1124-1129.
12. Asare, G. A.; Mossanda, K. S.; Kew, M. C.; Paterson, A. C.; Kahler- Venter, C. P.; Siziba, K. Hepatocellular carcinoma caused by iron overload: a possible mechanism of direct hepatocarcinogenicity. Toxicology, 2006, 219, 41-52.
13. Stal, P.; Broome, U.; Scheynius, A.; Befrits, R.; Hultcrantz, R. Kupffer cell iron overload induces intercellular adhesion molecule- 1 expression on hepatocytes in genetic hemochromatosis. Hepatology (Baltimore, Md), 1995, 21, 1308-1316.
14. George, D. K.; Goldwurm, S.; MacDonald, G. A.; Cowley, L. L.; Walker, N. I.; Ward, P. J.; Jazwinska, E. C.; Powell, L. W. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology, 1998, 114, 311- 318.
15. Fletcher, L. M.; Bridle, K. R.; Crawford, D. H. Effect of alcohol on iron storage diseases of the liver. Best Pract. & Res., 2003, 17, 663- 677.
16. Messner, D. J.; Kowdley, K. V. Neoplastic transformation of rat liver epithelial cells is enhanced by non-transferrin-bound iron. BMC Gastroenterol., 2008, 8, 2.
17. Tondury, P.; Zimmermann, A.; Nielsen, P.; Hirt, A. Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients. Br. J. Haematol., 1998, 101, 413-415.
18. Bhavnani, M.; Lloyd, D.; Bhattacharyya, A.; Marples, J.; Elton, P.; Worwood, M. Screening for genetic haemochromatosis in blood samples with raised alanine aminotransferase. Gut, 2000, 46, 707- 710.
19. Fischer, R.; Piga, A.; Harmatz, P.; Nielsen, P. Monitoring longterm efficacy of iron chelation treatment with biomagnetic liver susceptometry. Ann. NY. Acad. Sci., 2005, 1054, 350-357.
20. St Pierre, T. G.; Clark, P. R.; Chua-anusorn, W.; Fleming, A. J.; Jeffrey, G. P.; Olynyk, J. K.; Pootrakul, P.; Robins, E.; Lindeman, R. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood, 2005, 105, 855-861.
21. Thakerngpol, K.; Sonakul, D.; Fucharoen, S.; Vathanopas, V.; Stitnimankarn, T. Histochemical study of liver tissue from thalassemic patients. Birth Defects Orig. Artic. Ser., 1988, 23, 193-198.
22. Meo, A.; Ruggeri, A.; La Rosa, M. A.; Zanghi, L.; Morabito, N.; Duca, L. Iron burden and liver fibrosis decrease during a long-term phlebotomy program and iron chelating treatment after bone marrow transplantation. Hemoglobin, 1006, 30, 131-137.
23. Nielsen, P.; Fischer, R.; Engelhardt, R.; Tondury, P.; Gabbe, E. E.; Janka, G. E. Liver iron stores in patients with secondary haemosiderosis under iron chelation therapy with deferoxamine or deferiprone. Br. J. Haematol., 1995, 91, 827-833.
24. Britton, R. S.; Leicester, K. L.; Bacon, B. R. Iron toxicity and chelation therapy. Int. J. Hematol., 2002, 76, 219-228.
25. Cappellini, M. D. Long-term efficacy and safety of deferasirox. Blood Rev., 2008, 22 Suppl 2,S35-41.
26. Cappellini, M. D.; Piga, A. Current status in iron chelation in hemoglobinopathies. Cur. Mol. Med., 2008, 8, 663-674.
27. Ounjaijean, S. Iron-chelating property of green tea extract in ironoverload status. M.Sc. Thesis Chiang Mai Universiy, 2004.
28. Srichairatanakool, S.; Ounjaijean, S.; Thephinlap, C.; Khansuwan, U.; Phisalpong, C.; Fucharoen, S. Iron-chelating and free-radical scavenging activities of microwave-processed green tea in iron overload. Hemoglobin, 2006, 30, 311-327.
29. Chen, Z.; Zhu, Q. Y.; Tsang, D.; Huang, Y. Degradation of green tea catechins in tea drinks. J. Agric. Food Chem. 2001, 49, 477- 482.
30. Jamsai, D., Zaibak, F., Khongnium, W., Vadolas, J., Voullaire, L., Fowler, K.J., Gazeas, S., Fucharoen, S., Williamson, R., Ioannou, P.A. A humanized mouse model for a common-thalassemia mutation. Genomics 2005, 85, 453-461.
31. Jamsai, D., Zaibak, F., Vadolas, J., Voullaire, L., Fowler, K.J., Gazeas, S., Peters, H., Fucharoen, S., Williamson, R., Ioannou, P.A. A humanized BAC transgenic/knockout mouse model for HbE/β-thalassemia. Genomics, 2006, 88, 309-315.
32. Incharoen, T., Thephinlap, C., Srichairatanakool, S., Chattipakorn, S., Winichagoon, P., Fucharoen, S., Vadolas, J., Chattipakorn, N. Heart rate variability in β-thalassemic mice. Int. J. Cardiol., 2007, 121, 203-204.
33. King, J. W.; Willis, C. E. Cyanmethemoglobin certification program of the College of American Pathologists. Am. J. Clin. Pathol., 1970, 54, 496-501.
34. Fischer, D. S. a. P., D.C. A simple serum iron method using the new sensitive chromogen tripyridyl-s-triazine. Clin. Chem., 1964, 10, 21-31.
35. Imbert-Bismut, F.; Charlotte, F.; Turlin, B.; Khalil, L.; Piton, A.; Brissot, P.; Le Charpentier, Y.; Delattre, J.; Opolon, P.; Deugnier, Y.; Poynard, T. Low hepatic iron concentration: evaluation of two complementary methods, colorimetric assay and iron histological scoring. J. Clin. Pathol., 1999, 52, 430-434.
36. Cighetti, G.; Duca, L.; Bortone, L.; Sala, S.; Nava, I.; Fiorelli, G.; Cappellini, M. D. Oxidative status and malondialdehyde in betathalassaemia patients. Eur. J. Clin. Invest., 2002, 32 Suppl 1, 55- 60.
37. Thephinlap, C.; Phisalaphong, C.; Fucharoen, S.; Porter, J. B.; Srichairatanakool, S. Efficacy of curcuminoids in alleviation of iron overload and lipid peroxidation in thalassemic mice. Med. Chem., 2009, 5, 474-482.
38. Ounjaijean, S.; Thephinlap, C.; Khansuwan, U.; Phisalapong, C.; Fucharoen, S.; Porter, J. B.; Srichairatanakool, S. Effect of green tea on iron status and oxidative stress in iron-loaded rats. Med. Chem., 2008, 4, 365-370.
39. Ginzburg, Y. Z.; Rybicki, A. C.; Suzuka, S. M.; Hall, C. B.; Breuer, W.; Cabantchik, Z. I.; Bouhassira, E. E.; Fabry, M. E.; Nagel, R. L. Exogenous iron increases hemoglobin in betathalassemic mice. Exp. Hematol., 2009, 37, 172-183.
40. Bacon, B. R.; Britton, R. S. Hepatic injury in chronic iron overload. Role of lipid peroxidation. Chemico-Biol. Interact., 1989, 70, 183- 226.
41. Thakerngpol, K.; Fucharoen, S.; Boonyaphipat, P.; Srisook, K.; Sahaphong, S.; Vathanophas, V.; Stitnimankarn, T. Liver injury due to iron overload in thalassemia: histopathologic and ultrastructural studies. Biometals, 1996, 9, 177-183.
42. Aldouri, M. A.; Wonke, B.; Hoffbrand, A. V.; Flynn, D. M.; Laulicht, M.; Fenton, L. A.; Scheuer, P. J.; Kibbler, C. C.; Allwood, C. A.; Brown, D.; et al. Iron state and hepatic disease in patients with thalassaemia major, treated with long term subcutaneous desferrioxamine. J. Clin. Pathol., 1987, 40, 1353-1359.
43. Abe, K.; Ijiri, M.; Suzuki, T.; Taguchi, K.; Koyama, Y.; Isemura, M. Green tea with a high catechin content suppresses inflammatory cytokine expression in the galactosamine-injured rat liver. Biomed. Res., 2005, 26, 187-192.
44. Anghileri, L. J.; Thouvenot, P. Natural polyphenols-iron interaction: its biological importance. Biol. Trace Elem. Res., 2000, 73, 251-258.
45. Galati, G.; Lin, A.; Sultan, A. M.; O'Brien, P. J. Cellular and in vivo hepatotoxicity caused by green tea phenolic acids and catechins. Free Radic. Biol. Med., 2006, 40, 570-580.
46. Greger, J. L.; Lyle, B. J. Iron, copper and zinc metabolism of rats fed various levels and types of tea. J. Nutr., 1988, 118, 52-60.
47. Sakata, R.; Ueno, T.; Nakamura, T.; Sakamoto, M.; Torimura, T.; Sata, M. Green tea polyphenol epigallocatechin-3-gallate inhibits platelet-derived growth factor-induced proliferation of human hepatic stellate cell line LI90. J. Hepatol., 2004, 40, 52-59.
48. Nakamuta, M.; Higashi, N.; Kohjima, M.; Fukushima, M.; Ohta, S.; Kotoh, K.; Kobayashi, N.; Enjoji, M. Epigallocatechin-3- gallate, a polyphenol component of green tea, suppresses both collagen production and collagenase activity in hepatic stellate cells. Int. J. Mol. Med., 2005, 16, 677-681.
49. Yumei, F.; Zhou, Y.; Zheng, S.; Chen, A. The antifibrogenic effect of (-)-epigallocatechin gallate results from the induction of de novo synthesis of glutathione in passaged rat hepatic stellate cells. Lab. Invest., 2006, 86, 697-709.
50. Omara, F. O.; Blakley, B. R.; Huang, H. S. Effect of iron status on endotoxin-induced mortality, phagocytosis and interleukin-1 alpha and tumor necrosis factor-alpha production. Vet. Hum. Toxicol., 1994, 36, 423-428.
51. Zhong, Z.; Froh, M.; Connor, H. D.; Li, X.; Conzelmann, L. O.; Mason, R. P.; Lemasters, J. J.; Thurman, R. G. Prevention of hepatic ischemia-reperfusion injury by green tea extract. Am. J. Physiol. Gastrointest. Liver Physiol., 2002, 283, G957-964.